Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

This review evaluates the systemic absorption and pharmacokinetics of five novel topical dermatologic agents: ruxolitinib, tirbanibulin, clascoterone, minocycline, and tapinarof. These agents offer targeted treatments with improved safety and tolerability compared to traditional therapies. Ruxolitinib, effective for vitiligo and atopic dermatitis, shows low systemic absorption with bioavailability of 5.68% and 6.22% in trials. Tirbanibulin and clascoterone provide novel treatments for actinic keratoses and acne, respectively, with minimal systemic side effects. Minocycline foam addresses antibiotic resistance, and tapinarof is approved for psoriasis and atopic dermatitis. The review emphasizes the importance of understanding these agents' pharmacokinetic and pharmacodynamic properties for safe and effective clinical use.